EGFR and neoplasm: While it remains elusive whether all these substrates are involved in PTPN13 suppression of gefitinib resistance, our findings highlighted the role of Src inactivation in PTPN13-mediated gefitinib sensitization of NSCLCs, consistent with the previous finding that PTPN13 functions in NSCLCs as a tumor suppressor whose loss increases signaling from EGFR and HER2 [50].